Рецепт. 2022; : 69-75
Терапевтические перспективы применения препаратов Новинет и Регулон у женщин раннего репродуктивного возраста
https://doi.org/10.34883/PI.2022.25.1.001Аннотация
В обзоре представлены сведения о применении дезогестрела у женщин раннего репродуктивного возраста с различными вариантами нарушений менструального цикла. Согласно данным, дезогестрел можно рекомендовать как в режиме монотерапии, так и при комплексной терапии нарушений менструального цикла у женщин молодого возраста с различной соматической патологией. Данный подход позволяет снизить экономические затраты и максимально сузить зоны риска при гормональной терапии у пациенток с экстрагенитальной патологией.
Список литературы
1. Bogdanova E.A. Gynecology of Children and Adolescents. М., 2000; 332 p. (in Russian)
2. Vihlyaeva E.M. Hyperprolactinemia and the Reproductive System Disorder. Handbook of Endocrine Gynecology. М., 1997;343–360. (in Russian)
3. Gaivoronskaya S.I., Samoilova M.V., Mal’cev G.V., Blagoveshchenskii E.V., Vygovskaya L.A. The Use of Cardonate in the Complex Therapy of Reproductive Disorders in Girls. 2011. (in Russian)
4. Gurkin Yu.A. Gynecology of Adolescents: A Guide for Physicians. SPb, 2000. (in Russian)
5. Uvarova E.V. Problems of Adolescents and Youth in the Aspect of Demographic and Social Security in Russia. Reproductive Health of Children and Adolescents. 2010;6:16–32. (in Russian)
6. Uvarova E.V. Gynecology of Children and Adolescents. М.: Literra. 2008;8–44. (in Russian)
7. Federal Law No. 323 On the Fundamentals of Health Protection in the Russian Federation of November 21, 2011 as amended on July 3, 2016. (in Russian)
8. Antenatal Care. Routine Care for the Healthy Pregnant Women. NICE. Clinical Guideline. March 2008. 2d ed.
9. Barnhart K.T., Schreiber C.A. Return to fertility following discontinuation of oral contraceptives. Fertil. Steril. 2009;91:659–663.
10. Brown J. Nutrition through the life cycle. 3rd ed. Thomson Wadsworth. 2008;109–1102.
11. Centers for Disease Control and Prevention (CDC). MMWR Surveill Summ. 2009;58(SS-6):1–58.
12. Clark L.R. Will the pill make me sterile? Addressing reproductive health concerns and strategies to improve adherence to hormonal contraceptive regimens in adolescent girls. J. Pediatr. Adolesc. Gynecol. 2001;14:153–162.
13. De-Regil L.M., Pena-Rosas J.P., Fernandez-Gaxiola A.C. Effects and safety of periconceptional folate supplementation for preventing birth defects. Cochrane Database Syst. Rev. 2010;10.
14. Allais G., Gabellari I.C., Airola G., Borgogno P., Schiapparelli P., Benedetto C. Headache induced by the use of combined oral contraceptives. Neurol Sci. 2009;30(1):15–17.
15. Aegidius K., Zwart J.A., Hagen K., Schei B., Stovner L.J. Oral contraceptives and increased headache prevalence: the Head-HUNT Study. Neurology. 2006; 66(3):349–353.
16. The European Active Surveillance study on Oral Contraceptives based on 142,475 women-years of observation. Contraception. 2007;75:344–354.
17. Dinger J., Minh T.D., Buttmann N. Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen. Obstet. Gynecol. 2011;117:33–40.
18. Gallo M.F., Lopez L.M., Grimes D.A. Combination contraceptives: effects on weight. (Cochrane Review). The Cochrane Library. Oxford: Update Software, 2006. Issue 1.
19. Loder E.W., Buse D.C., Golub J.R. Headache as a side effect of combination estrogen-progestin oral contraceptives: a systematic review. Am J Obstet Gynecol. 2005;193(3 Pt 1):636–649.
20. Gavin L., MacKay A.P., Brown K. Sexual and reproductive health of persons aged 10–24 years. United States, 2002–2007.
21. Guilbert E., Boroditsky R., Black A., Society of Obstetricians and Gynaecologists of Canada. Canadian Consensus Guideline on Continuous and Extended Hormonal Contraception, 2007. J. Obstet. Gynaecol. Can. 2007;29(2):1–32.
22. Teepker M., Peters M., Kundermann B., Vedder H., Schepelmann K., Lautenbacher S. The effects of oral contraceptives on detection and pain thresholds as well as headache intensity during menstrual cycle in migraine. Headache. 2011;51(1):92–104.
23. Harlow S.D., Gass M., Hall J.E., STRAW 10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. Menopause. 2012;19(4):387–395.
24. Klipping C., Duljkers I., Trummer D. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception. 2008;78:16–25.
Recipe. 2022; : 69-75
Therapeutic Prospects of Novinette and Regulon in Women of Early Reproductive Age
https://doi.org/10.34883/PI.2022.25.1.001Abstract
In this review, the information on the use of desogestrel in women of early reproductive age with various types of menstrual irregularities is provided. According to the data, desogestrel can be recommended both in monotherapy and in complex therapy of menstrual disorders in young women with various somatic pathologies. This approach allows to reduce economic costs and to narrow risk zones during hormone therapy in patients with extragenital pathology.
References
1. Bogdanova E.A. Gynecology of Children and Adolescents. M., 2000; 332 p. (in Russian)
2. Vihlyaeva E.M. Hyperprolactinemia and the Reproductive System Disorder. Handbook of Endocrine Gynecology. M., 1997;343–360. (in Russian)
3. Gaivoronskaya S.I., Samoilova M.V., Mal’cev G.V., Blagoveshchenskii E.V., Vygovskaya L.A. The Use of Cardonate in the Complex Therapy of Reproductive Disorders in Girls. 2011. (in Russian)
4. Gurkin Yu.A. Gynecology of Adolescents: A Guide for Physicians. SPb, 2000. (in Russian)
5. Uvarova E.V. Problems of Adolescents and Youth in the Aspect of Demographic and Social Security in Russia. Reproductive Health of Children and Adolescents. 2010;6:16–32. (in Russian)
6. Uvarova E.V. Gynecology of Children and Adolescents. M.: Literra. 2008;8–44. (in Russian)
7. Federal Law No. 323 On the Fundamentals of Health Protection in the Russian Federation of November 21, 2011 as amended on July 3, 2016. (in Russian)
8. Antenatal Care. Routine Care for the Healthy Pregnant Women. NICE. Clinical Guideline. March 2008. 2d ed.
9. Barnhart K.T., Schreiber C.A. Return to fertility following discontinuation of oral contraceptives. Fertil. Steril. 2009;91:659–663.
10. Brown J. Nutrition through the life cycle. 3rd ed. Thomson Wadsworth. 2008;109–1102.
11. Centers for Disease Control and Prevention (CDC). MMWR Surveill Summ. 2009;58(SS-6):1–58.
12. Clark L.R. Will the pill make me sterile? Addressing reproductive health concerns and strategies to improve adherence to hormonal contraceptive regimens in adolescent girls. J. Pediatr. Adolesc. Gynecol. 2001;14:153–162.
13. De-Regil L.M., Pena-Rosas J.P., Fernandez-Gaxiola A.C. Effects and safety of periconceptional folate supplementation for preventing birth defects. Cochrane Database Syst. Rev. 2010;10.
14. Allais G., Gabellari I.C., Airola G., Borgogno P., Schiapparelli P., Benedetto C. Headache induced by the use of combined oral contraceptives. Neurol Sci. 2009;30(1):15–17.
15. Aegidius K., Zwart J.A., Hagen K., Schei B., Stovner L.J. Oral contraceptives and increased headache prevalence: the Head-HUNT Study. Neurology. 2006; 66(3):349–353.
16. The European Active Surveillance study on Oral Contraceptives based on 142,475 women-years of observation. Contraception. 2007;75:344–354.
17. Dinger J., Minh T.D., Buttmann N. Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen. Obstet. Gynecol. 2011;117:33–40.
18. Gallo M.F., Lopez L.M., Grimes D.A. Combination contraceptives: effects on weight. (Cochrane Review). The Cochrane Library. Oxford: Update Software, 2006. Issue 1.
19. Loder E.W., Buse D.C., Golub J.R. Headache as a side effect of combination estrogen-progestin oral contraceptives: a systematic review. Am J Obstet Gynecol. 2005;193(3 Pt 1):636–649.
20. Gavin L., MacKay A.P., Brown K. Sexual and reproductive health of persons aged 10–24 years. United States, 2002–2007.
21. Guilbert E., Boroditsky R., Black A., Society of Obstetricians and Gynaecologists of Canada. Canadian Consensus Guideline on Continuous and Extended Hormonal Contraception, 2007. J. Obstet. Gynaecol. Can. 2007;29(2):1–32.
22. Teepker M., Peters M., Kundermann B., Vedder H., Schepelmann K., Lautenbacher S. The effects of oral contraceptives on detection and pain thresholds as well as headache intensity during menstrual cycle in migraine. Headache. 2011;51(1):92–104.
23. Harlow S.D., Gass M., Hall J.E., STRAW 10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. Menopause. 2012;19(4):387–395.
24. Klipping C., Duljkers I., Trummer D. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception. 2008;78:16–25.
